Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings
18/07/2026 20:20
BRIEF-4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings July 18 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O:
4DMT ANNOUNCES POSITIVE 2-YEAR DATA FROM PRISM PHASE 2B CLINICAL TRIAL IN A BROAD WET AMD POPULATION
4D MOLECULAR THERAPEUTICS - 4D-150 CONTINUES TO BE WELL TOLERATED WITH NO NEW SAFETY FINDINGS
Source text: ID:nGNX80nHf5
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings